Provide dose justification and information on global standards, the CDSCO panel instructs Synokem regarding Sacubitril and valsartan FDC.

Published Date: 28 Aug 2023

In response to the clinical trial protocol for the medication mix of sacubitril and valsartan presented by the pharmaceutical company Synokem, the.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: When will individuals be able to receive customized cancer vaccines?

2.

Canadian Group Calls for Earlier Colorectal Cancer Screening

3.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

4.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

5.

Talquetamab Combos Show Survival Benefit in r/r Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot